生物活性 | |||
---|---|---|---|
描述 | The N-methyl-D-aspartate receptor (NMDAR) is involved in normal physiological and pathological states in the brain[3]. The NMDA-preferring glutamate receptor subtype possesses, in addition to the recognition site for glutamate, a binding site for glycine. MDL-29951 is a novel glycine antagonist of NMDA receptor activation with a Ki value of 0.14 μM. It is approximately 2000-fold selective for the glycine binding site over the glutamate recognition sites. MDL-29951 completely inhibited the use-dependent binding of [3H]N-[1-(2-thienyl) cyclohexyl]-piperidine and was noncompetitive, glycine-reversible inhibitor of both NMDA-induced biochemical and electrophysiological responses in brain slice preparations[4]. In addition, MDL-29951 was found to inhibit the human F16Bpase (Fructose-1,6-bisphosphatase; one of the rate limiting enzymes of hepatic gluconeogenesis) with an IC50 of 2.5 μM[5]. Moreover, MDL-29951 diminished myelination in primary oligodendrocytes isolated from heterozygous mice[6]. MDL-29951 was potent anticonvulsants after their i.c.v. administration to audiogenic seizure-susceptible DBA/2J mice[4]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.31mL 0.66mL 0.33mL |
16.55mL 3.31mL 1.66mL |
33.10mL 6.62mL 3.31mL |
参考文献 |
---|